Company profile for Portage Biotech

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Despite advances in the immuno-oncology field, 70-80% of patients do not respond or have a limited response to existing therapies, such as checkpoint inhibitors. Portage Biotech aims to change this with a unique approach that drives the development of first-in-class immuno-oncology therapies for patients with cancer. We know quality science and leverage our team’s deep knowledge to create a viable product development strat...
Despite advances in the immuno-oncology field, 70-80% of patients do not respond or have a limited response to existing therapies, such as checkpoint inhibitors. Portage Biotech aims to change this with a unique approach that drives the development of first-in-class immuno-oncology therapies for patients with cancer. We know quality science and leverage our team’s deep knowledge to create a viable product development strategy that supports commercial potential and company growth. We execute the development process and create strategies to guide novel immuno-oncology assets and asset combinations from bench through human proof of concept.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
Clarence Thomas Building, (302) 219-5556 P.O. Box 4649, Road Town, Tortola, Br...
Telephone
Telephone
416.929.1806
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/07/25/3121999/0/en/Portage-Biotech-Reports-Results-for-Fiscal-Year-Ended-March-31-2025.html

GLOBENEWSWIRE
25 Jul 2025
Portage Biotech Regains Nasdaq Compliance
Portage Biotech Regains Nasdaq Compliance

25 Jun 2025

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2025/06/25/3104952/0/en/Portage-Biotech-Regains-Full-Compliance-with-Nasdaq-Continued-Listing-Requirements.html

GLOBENEWSWIRE
25 Jun 2025

https://www.globenewswire.com/news-release/2025/06/09/3095684/0/en/Portage-Biotech-and-Compedica-Stock-for-Stock-Exchange.html

GLOBENEWSWIRE
09 Jun 2025

https://www.globenewswire.com/news-release/2025/04/28/3068995/0/en/Portage-Biotech-Reports-Confirmatory-Preclinical-Results-in-Mesothelioma-Supporting-First-In-Human-Trial-of-PORT-7.html

GLOBENEWSWIRE
28 Apr 2025

https://www.globenewswire.com/news-release/2025/03/27/3051025/0/en/Portage-Biotech-Reports-Promising-Preclinical-Results-in-Mesothelioma-Supporting-First-In-Human-Trial-of-PORT-7.html

GLOBENEWSWIRE
27 Mar 2025

https://www.globenewswire.com//news-release/2025/03/12/3041325/0/en/Portage-Biotech-Resumes-Enrollment-in-Final-Cohort-of-Dose-Escalation-for-Port-6-in-ADPORT-601-Trial.html

GLOBENEWSWIRE
12 Mar 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty